Entinostat - PDFSEARCH.IO - Document Search Engine

Entinostat
Results: 10

#	Item
1	Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea Tokyo, Japan, January 8, 2015 and Waltham, Mass., January 7, Kyowa Hakko Kirin Co., Add to Reading List Source URL: www.kyowa-kirin.com Language: English - Date: 2015-01-07 19:00:05
2	Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells Add to Reading List Source URL: www.nature.com Language: English - Date: 2013-03-21 11:00:58 Genetics MicroRNA Oncogenes RNA Mir-205 Trastuzumab Epidermal growth factor receptor Breast cancer HER2/neu Biology Medicine Tyrosine kinase receptors
3	FORM Approval of Press Releases Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-16 21:58:30 Hydroxamic acids Orphan drugs Lung cancer Histone deacetylase inhibitor Histone deacetylase Alkynes Vorinostat Entinostat Carcinogenesis Medicine Chemistry Organic chemistry
4	Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat — Extends exclusivity to 2029 supporting commercialization in breast and lung cancer — Waltham, Mass. – June 2, 2011 – Syndax Pharmaceuticals Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-16 21:58:31 Ribbon symbolism Histone deacetylase inhibitor Entinostat Erlotinib Breast cancer Metastatic breast cancer Histone deacetylase Metastasis Lung cancer Medicine Chemistry Organic chemistry
5	Syndax Pharmaceuticals Inc. to Present Entinostat Data Showing Benefit in Combination in Advanced Breast Cancer at ASCO WALTHAM, Mass., May 24 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics co Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-15 11:58:27 Ribbon symbolism Breast cancer Histone deacetylase inhibitor Entinostat Targeted therapy Exemestane Metastatic breast cancer Histone deacetylase Management of cancer Medicine Oncology Aromatase inhibitors
6	Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat — Company focused on moving entinostat into phase 3 clinical trial— Waltham, Mass. – August 17, 2011 – Syndax Pharmaceuticals, a clinical-stag Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-18 12:46:19 Aromatase inhibitors Oncology Metastatic breast cancer Entinostat Histone deacetylase inhibitor Aromatase Metastasis Breast cancer treatment Oncotype DX Medicine Breast cancer Ribbon symbolism
7	Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting Waltham, Mass. – March 31, 2011 – Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-15 11:58:26 Hydroxamic acids Orphan drugs Lung cancer Histone deacetylase inhibitor Histone deacetylase Alkynes Vorinostat Entinostat Carcinogenesis Medicine Oncology Chemistry
8	Syndax Pharmaceuticals’ Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients --Phase 2 data to be presented at 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology-Waltham, Mass. – December 9 Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-08-15 11:58:34 Chemistry Amines Quinazolines Alkynes Erlotinib Pfizer Non-small-cell lung carcinoma Protein kinase inhibitor Tyrosine kinase Medicine Oncology Lung cancer
9	Syndax Pharmaceutical’s Positive Phase 2 Data Supports Potential for Entinostat in Advanced Breast Cancer -- Entinostat in combination with exemestane prolonged progression-free survival --- Randomized, placebo-control Add to Reading List Source URL: www.forwardventures.com Language: English - Date: 2011-09-09 08:47:22 Breast cancer Ribbon symbolism Exemestane Pfizer Metastatic breast cancer Hormonal therapy Estrogen Aromatase Letrozole Medicine Aromatase inhibitors Endocrine system
10	Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers Company Prepares for Pivotal Phase 3 Study of Entinostat, Most Advanced HDAC Add to Reading List Source URL: www.syndax.com Language: English - Date: 2013-08-27 07:52:58 Histone deacetylase inhibitor Breast cancer Metastatic breast cancer Entinostat Targeted therapy Cancer research Metastasis Epigenetics Breast cancer treatment Medicine Ribbon symbolism Oncology

UPDATE